Skip to content
10-K

Annual Report

KAIROS PHARMA, LTD. KAPA

0001493152-26-014159

← back to feed
Filed
Mar 31, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 31, 2026 21.41M sh
Shares Diluted FY 2025 · Dec 31, 2025 18.43M sh
Shares Diluted FY 2025 · Dec 31, 2024 11.36M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$3.44M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$3.96M
Cash And Equivalents FY 2025 · Dec 31, 2025 $4.49M
Cash And Equivalents FY 2025 · Dec 31, 2024 $1.27M
Stockholders Equity FY 2025 · Dec 31, 2025 $6.34M
Stockholders Equity FY 2025 · Dec 31, 2024 $4.78M
Stockholders Equity FY 2025 · Dec 31, 2023 −$2.08M
Current Liabilities FY 2025 · Dec 31, 2025 $199K
Current Liabilities FY 2025 · Dec 31, 2024 $992K
Current Assets FY 2025 · Dec 31, 2025 $5.39M
Current Assets FY 2025 · Dec 31, 2024 $4.17M
Total Assets FY 2025 · Dec 31, 2025 $6.54M
Total Assets FY 2025 · Dec 31, 2024 $5.77M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.30
Eps Diluted FY 2025 · Dec 31, 2024 −$0.23
Eps Basic FY 2025 · Dec 31, 2025 −$0.30
Eps Basic FY 2025 · Dec 31, 2024 −$0.23
Sga Expense FY 2025 · Dec 31, 2025 $3.44M
Sga Expense FY 2025 · Dec 31, 2024 $1.93M
Rd Expense FY 2025 · Dec 31, 2025 $2.14M
Rd Expense FY 2025 · Dec 31, 2024 $414K
Net Income FY 2025 · Dec 31, 2025 −$5.45M
Net Income FY 2025 · Dec 31, 2024 −$2.6M
Operating Income FY 2025 · Dec 31, 2025 −$5.57M
Operating Income FY 2025 · Dec 31, 2024 −$2.34M